PROJECT AEROVIA-CF1A
SCF API Discovery Program for Cystic Fibrosis
Program Code: SCF-CF-S3-0001
Objective:
Convert the Stage 2 therapeutic architecture into a defined pharmaceutical candidate platform by identifying specific APIs, assigning SCF roles, defining molecular mechanisms, and constructing a translationally viable development candidate.
I. PRIMARY DEVELOPMENT SELECTION
After Stage 2 prioritization, the highest-value development path remains:
AEROVIA-CF1A
Therapeutic Class:
Multi-Target Inhaled Disease-Modifying Therapy
Intended Use:
Adjunct to CFTR modulators and treatment for modulator-nonresponsive CF populations.
II. SCF REVERSE-ENGINEERED TARGET ARCHITECTURE
Tier 1 Disease Drivers
Driver | Molecular Node | Therapeutic Goal |
Biofilm persistence | Quorum sensing / alginate | Collapse biofilm |
Neutrophilic inflammation | IL-8/CXCR2 | Reduce recruitment |
Tissue destruction | Neutrophil elastase | Preserve lung architecture |
Fibrosis | TGF-β/SMAD | Prevent remodeling |
Oxidative stress | Nrf2 pathways | Restore redox balance |
III. LEAD API CANDIDATE GENERATION
API-1
CFX-101
Working Name: Cystaflexor
SCF Classification:
Target-Specific Modulator
Mechanism
Dual-function anti-biofilm molecule:
- Quorum-sensing disruption
- Alginate synthesis suppression
Intended Effect
Disrupt chronic microbial persistence.
Therapeutic Role
Curative
API-2
CFX-201
Working Name: Elastamir
SCF Classification: Safety Harmonizer
Mechanism
Selective neutrophil elastase inhibition.
Intended Effect
Prevent irreversible airway destruction.
Therapeutic Role
Curative + Restorative
API-3
CFX-301
Working Name: Fibrosquel
SCF Classification:
Restorative Modulator
Mechanism
Partial TGF-β pathway modulation.
Intended Effect
Prevent excessive ECM remodeling while preserving physiological repair.
Therapeutic Role
Restorative
API-4
CFX-401
Working Name: Mitogard
SCF Classification:
Metabolic Regulator
Mechanism
Nrf2 activation and mitochondrial resilience enhancement.
Intended Effect
Reduce ROS-mediated injury and improve epithelial recovery.
Therapeutic Role
Restorative
IV. PROPOSED SCF FIBONACCI STACK
F1 — Target Modulator
CFX-101
Biofilm collapse
F1 — Safety Harmonizer
CFX-201
Elastase suppression
F2 — Metabolic Regulators
CFX-301
CFX-401
F3 — Delivery Layer
- Muco-penetrating nanoparticle
- Liposomal aerosol carrier
- Dry-powder inhalation platform
F5 — Supportive Layer
Future optimization candidates:
- Oxindole alkaloid analogs
- Taspine analogs
- Cordycepin analogs
- Glutathione-enhancing molecules
- ECM stabilizers
V. PRELIMINARY API DISCOVERY PROFILES
CFX-101
API Index Code
SCF-CF-API-101
Therapeutic Class
Anti-Biofilm Pulmonary Agent
Mechanism of Action (MeA)
Disruption of quorum sensing signaling and extracellular matrix synthesis pathways.
Mode of Action (MoA)
Reduction of microbial communication and biofilm integrity.
Primary Biomarkers
- Sputum bacterial burden
- Biofilm density markers
- Pulmonary exacerbation rate
CFX-201
API Index Code
SCF-CF-API-201
Therapeutic Class
Selective Elastase Modulator
Mechanism of Action
Inhibition of neutrophil elastase catalytic activity.
Mode of Action
Reduction of protease-mediated tissue destruction.
Primary Biomarkers
- Neutrophil elastase
- MMP-9
- FEV1
CFX-301
API Index Code
SCF-CF-API-301
Therapeutic Class
Anti-Fibrotic Modulator
Mechanism of Action
Partial attenuation of TGF-β signaling.
Mode of Action
Reduction of fibroblast overactivation.
Biomarkers
- TGF-β
- Collagen turnover markers
- CT fibrosis imaging
CFX-401
API Index Code
SCF-CF-API-401
Therapeutic Class
Mitochondrial Recovery Agent
Mechanism of Action
Activation of antioxidant response pathways.
Mode of Action
Reduction of oxidative injury.
Biomarkers
- Glutathione
- ROS markers
- Mitochondrial function assays
VI. PRELIMINARY SYNERGY MODEL
Based on SCF synergy framework principles:
Metric | Expected Performance |
TSSM | High |
HSV-F² | High |
SV-EQ | High |
MGIS | Moderate–High |
SPCI | High |
Synergy Logic
CFX-101 reduces microbial persistence.
↓
CFX-201 decreases tissue injury.
↓
CFX-301 prevents structural remodeling.
↓
CFX-401 restores cellular resilience.
↓
Enhanced preservation of lung function.
VII. TRANSLATIONAL DEVELOPMENT STRATEGY
Route
Inhalation
Advantages
- High local exposure
- Reduced systemic toxicity
- Direct lung targeting
- Lower required dose
Target Population
Cohort A
Patients receiving CFTR modulators with persistent disease.
Cohort B
Rare mutation populations.
Cohort C
Advanced CF lung disease.
VIII. STAGE 3 DECISION GATE
Criterion | Status |
Biological Plausibility | PASS |
Multi-Target Coverage | PASS |
Biomarker Tractability | PASS |
Inhalation Feasibility | PASS |
Regulatory Feasibility | PASS |
Competitive Differentiation | PASS |
STAGE 3 OUTCOME
ADVANCE TO STAGE 4 — LEAD OPTIMIZATION & PRECLINICAL CANDIDATE DESIGN
Stage 4 Objectives:
- Convert conceptual APIs into actual molecular entities.
- Design scaffold structures.
- Define physicochemical requirements.
- Establish inhalation PK/PD goals.
- Create candidate selection matrix.
- Perform safety-risk modeling.
- Generate FDA-aligned preclinical development package.
Critical Note
At this point, the program transitions from disease and target analysis into actual drug-candidate engineering. Any further progression should distinguish clearly between:
- Evidence-supported known molecules and targets.
- Hypothetical novel candidates requiring medicinal chemistry, modeling, and experimental validation.
No efficacy or safety can be assumed until preclinical studies are performed.
MASTER REGISTRY INDEX
SCF-CF-S3-0001 — API Discovery & Molecular Engineering
SCF-CF-API-101 — CFX-101 Anti-Biofilm Program
SCF-CF-API-201 — CFX-201 Elastase Modulator Program
SCF-CF-API-301 — CFX-301 Anti-Fibrotic Program
SCF-CF-API-401 — CFX-401 Mitochondrial Recovery Program
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-API-DP-0001 — SCF API Discovery Profile Framework
SCF-FDA-IND-0001 — FDA Translational Development Framework